Related Experiment Videos
Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines
1Thyroid Cancer Research Laboratory, Medical Service, Veterans Affairs Medical Center, Lexington, Kentucky 40511, USA.
The Journal of Clinical Endocrinology and Metabolism
|June 1, 1997
Summary
Somatostatin analogs can inhibit thyroid cancer cell growth by targeting somatostatin receptors (SSTRs). This study identified SSTR3 and SSTR5 as commonly expressed in thyroid tumors, suggesting potential therapeutic strategies.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Somatostatin (SRIH) analogs show potential in suppressing human differentiated thyroid carcinoma (DTC) cell proliferation.
- The expression of somatostatin receptors (SSTRs) is crucial for this inhibitory effect.
- Five human SSTR subtypes (hSSTR1-5) exist, with varying affinities to SRIH analogs.
Purpose of the Study:
- To investigate the expression patterns of SSTR subtypes in various human thyroid carcinoma cell lines and normal thyroid tissues.
- To determine if SSTR expression differs between in vitro monolayer cultures and in vivo xenograft models.
- To assess the potential for targeting SSTRs with SRIH analogs for thyroid cancer therapy.
Main Methods:
- Reverse transcriptase-PCR amplification was used to detect SSTR subtype messenger RNAs (mRNAs).
- Analysis was performed on normal thyroid tissues and nine human thyroid carcinoma cell lines (follicular adenoma, follicular carcinoma, papillary carcinoma, anaplastic carcinoma).
- Both monolayer cultures and xenograft tumors in nude mice were analyzed.
Main Results:
- Most thyroid cancer cell lines and xenografts expressed SSTR3 and SSTR5 mRNAs.
- SSTR1 expression varied, while SSTR2 and SSTR4 mRNA were detected at very low levels.
- Normal thyroid tissue also expressed SSTR3 and SSTR5, with limited SSTR1 and SSTR2 expression.
- SSTR mRNA expression levels were influenced by culture conditions, often decreasing in xenografts compared to monolayers.
Conclusions:
- SSTR3 and SSTR5 are frequently expressed in human thyroid carcinomas.
- Understanding SSTR subtype expression is key to developing targeted SRIH analog therapies.
- SRIH analogs may offer a therapeutic strategy for both differentiated and anaplastic thyroid carcinomas.